Bio

Clinical Focus

  • Obstetrics and Gynecology
  • General Obstetrics
  • Minimally Invasive Surgery
  • Fibroid
  • Abnormal vaginal bleeding
  • Ovarian Cysts
  • Prenatal Care
  • PCOS
  • Vaginitis
  • Contraception
  • Abnormal Pap Smear/ Colposcopy
  • Women's Preventative Health
  • Menopause health/ Hormone treatment

Administrative Appointments

  • Director, Gynecology Simulation Education Program (2014 - Present)

Honors & Awards

  • Outstanding Faculty Professor of Gynecology, Resident Staff of Stanford Obstetrics and Gynecology (2013-2014)
  • Administrative Chief Resident, UCLA Department of Obstetrics and Gynecology, Elected by Resident Staff (2012-2013)
  • Outstanding Resident Research Award, UCLA Department of Obstetrics and Gynecology (2012)
  • Alpha Omega Alpha Honor Medical Society, UCLA David Geffen School of Medicine (2009)

Boards, Advisory Committees, Professional Organizations

  • Member, National OB/Gyn Simulation Consortium, ACOG (2014 - Present)
  • Member, American Association of Gynecologic Laparoscopists (AAGL) (2012 - Present)
  • Member, American Congress of Obstetrics and Gynecology (ACOG) (2008 - Present)

Professional Education

  • Residency: UCLA David Geffen School Of Medicine Registrar (2013) CA
  • Medical Education: UCLA David Geffen School Of Medicine Registrar (2009) CA
  • Board Certification: American Board of Obstetrics and Gynecology, Obstetrics and Gynecology (2015)
  • Bachelor of Science, UCLA, Microbiology, Immunology & Molecular Genetics (2004)

Community and International Work

  • Medicine for Humanity, Mbara University of Science and Technology, Uganda

    Topic

    Vaginal Fistula Treatment

    Partnering Organization(s)

    Medicine for Humanity

    Populations Served

    Uganda, Africa

    Location

    International

    Ongoing Project

    No

    Opportunities for Student Involvement

    No

Contact

  • OB GYN Academic Office
    • Tel: (650) 725-5986
  • Obstetrics and Gynecology 300 Pasteur Dr Rm H302A MC 5317 Stanford, CA 94305
    • Tel: (650) 498-8080
    Fax: (650) 723-7737

Research & Scholarship

Clinical Trials

  • Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor Recruiting

    Approximately 22% of term pregnancies are induced. Misoprostol, a prostaglandin E1 analogue, is a widely accepted induction agent, that has been proven safe and effective for induction of labor. It stimulates both cervical ripening and uterine contractions, thus making it an ideal induction agent for unfavorable cervices. Research has examined the pharmacokinetics of different administration routes and effects on uterine contractility, side effects, and safety. Vaginal misoprostol has been shown to be superior over oral administration however patients often prefer a more tolerable route. Buccal administration has already been shown to be as effective as vaginal misoprostol for cervical ripening and induction in both first trimester and second trimester abortions. There is minimal research comparing buccal versus vaginal for third trimester induction of labor. The investigators study is a prospective, double blinded, randomized control trial comparing vaginal misoprostol and buccal misoprostol in equal dosages of 25 mcg. The investigators seek to answer the question whether buccal misoprostol is as effective as vaginal misoprostol for third trimester induction of labor.

    View full details

Publications

All Publications

  • Evaluation of Patient Characteristics Associated With Mode of Hysterectomy and Conversion Rate. Journal of minimally invasive gynecology Pao, S. A., Tran, L. 2015; 22 (6S): S96-?

    View details for DOI 10.1016/j.jmig.2015.08.259

    View details for PubMedID 27679387

  • Evaluation of Patient Characteristics Associated With Mode of Hysterectomy and Conversion Rate Abstracts of the 44th AAGL Global Congress of Minimally Invasive Gynecology Pao, S., Tran, L. 2015: 110
  • Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Annals of the New York Academy of Sciences Wilson, L. L., Tran, L., Morton, D. L., Hoon, D. S. 2004; 1022: 317?22

    Abstract

    Tumor progression is a dynamic sequence of events that involves specific protein changes. We hypothesized that Surface Enhanced Laser Desorption/Ionization (SELDI) mass spectrometric analysis of sera from patients with AJCC stage I and II melanoma with negative loco-regional lymph nodes could identify potential melanoma-associated protein biomarkers of disease recurrence. Serum specimens were collected from 49 patients who developed recurrence (n = 25) or remained free of recurrence (n = 24) without evidence of disease following complete resection (AJCC stage I and II). Follow-up was longer than 5 years. Serum proteins were denatured and applied onto two protein chip chemistry surfaces (weak cationic WCX2; metal-binding, IMAC3-Cu). SELDI ProteinChip mass spectrometry was then performed. SELDI data were analyzed, protein peak clustering and classification were performed, and a supervised classification algorithm was employed to classify the dataset. Multiple protein peaks ranging from 3.3 to 30 kDa were identified between patients with recurrence and those without recurrence, and the expression pattern differences of three proteins were used to generate the discriminating classification tree. The biomarkers were expressed with a high degree of reproducibility. In this early characterization study, melanoma recurrence was predicted with a sensitivity of 72% (18/25) and a specificity of 75% (18/24). This novel pilot study revealed three proteins that accurately identified patients who developed recurrence after curative resection of primary melanoma.

    View details for DOI 10.1196/annals.1318.047

    View details for PubMedID 15251977

Footer Links:

Stanford Medicine Resources: